News | June 01, 2021
Jubilant to invest US $92 mn to expand sterile injectable capacity
This investment is being made to set up a high speed 400 vials a minute injectable fill line with isolator technology
This investment is being made to set up a high speed 400 vials a minute injectable fill line with isolator technology
Adjusted PAT declined 18.8% YoY
US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio
For the year ended March 31, 2021, consolidated revenue was at Rs. 10,943.9 crores as against Rs. 10,641 crores, recording an increase of 2.8% over the previous corresponding period
Mucormycosis drug AmphoTLC will be imported from Taiwan by Stelis Biopharma Private Limited (Stelis), the biotech arm of Strides group, and will be launched and distributed in India immediately by Strides
MEK inhibitor compound (LNP3794) developed as part of its oncology pipeline had previously shown pre-clinical activity as a single agent as well as in combination
Dr. Sharvil Patel cites the example of prescriptions being handed over to patients despite unavailability of enough stock of such medicines
The company reported net profit for FY21 at Rs. 2,903.8 crore, lower by 23% over last year
With the surge of infections in India in the recent days AmphoTLC will address the country's acute liposomal amphotericin B shortage
The antibody cocktail is to be administered for the treatment of mild to moderate COVID-19
Subscribe To Our Newsletter & Stay Updated
